Group by Gene: Include preclinical: | CD20 inhibitor rituximab | Alkylating agent cyclophosphamide | PI3Kδ inhibitor idelalisib | CD19-targeted CAR-T immunotherapy PZ01 | RIVAC | R-CVAD | Chemotherapy EPOCH-R | R-GDP | RICE | ViPOR | T-lymphocyte cell therapy T-lymphocyte cell therapy | CD20 inhibitor, Chemotherapy CODOX-M + rituximab | THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor, Chemotherapy RIVAC + methotrexate | RICE + methotrexate | THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Chemotherapy R-CVAD + cytarabine + methotrexate | Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor cytarabine + ifosfamide + etoposide IV + methotrexate | CD19 inhibitor, CD16A inhibitor, IL-15R stimulant, CD20 inhibitor rituximab + FT596 | CD38-targeted antibody-drug conjugate, Ionizing radiation emitter Actinium-225 conjugated to daratumumab | SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor MEDI7247 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | |||||||||||||||||||
TP53 T175H + PIK3CA H1047R | |||||||||||||||||||
CD20 positive | |||||||||||||||||||
LDH elevation | |||||||||||||||||||
TP53 A159V | |||||||||||||||||||
CD38 positive | |||||||||||||||||||
CD19 positive + CD20 positive | |||||||||||||||||||
LY9 expression | |||||||||||||||||||
SLC1A5 overexpression |